Neurochem Adds VP From Picchio
This article was originally published in The Pink Sheet Daily
Executive Summary
Neurochem has named former Picchio Pharma VP Andreas Orfanos to the newly created position of executive VP-strategic planning and scientific affairs.
You may also be interested in...
FDA Cardio-Renal Division Accepts Neurochem’s Fibrillex For Pilot 2 Program
Selection for the continuous marketing application program could expedite review of the amyloidosis treatment, which is targeted for NDA filing in 2005. The pilot 2 program builds upon an earlier collaboration between Neurochem and FDA through which the agency provided funding for a Fibrillex Phase II/III clinical trial.
Italy Leads European Push Into Conditional Reimbursement
Italy claims to have pushed farther into managed entry agreements than other European countries with strong clawback provisions on new drugs – particularly cancer drugs – if they don't work as well as their manufacturers claim. The financial clawbacks are supported by extensive outcome data collection across the country's twenty regions.
Changes To The NHS: How Can Pharma Best Position Itself?
The U.K.’s Health and Social Care Bill was introduced into Parliament on Jan. 19, offering a new commercial landscape best navigated by pharma through bolstered relationships with general practitioners.